Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
136
-
Total 13F shares, excl. options
-
48M
-
Shares change
-
+3.8M
-
Total reported value, excl. options
-
$2.15B
-
Value change
-
+$180M
-
Put/Call ratio
-
2.23
-
Number of buys
-
83
-
Number of sells
-
-50
-
Price
-
$44.88
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q2 2021
156 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q2 2021.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 136 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48M shares
of 62.2M outstanding shares and own 77.2% of the company stock.
Largest 10 shareholders include FMR LLC (7.12M shares), BVF INC/IL (3.75M shares), RTW INVESTMENTS, LP (3.51M shares), Consonance Capital Management LP (3.45M shares), BlackRock Inc. (3.04M shares), Johnson & Johnson Innovation - JJDC, Inc. (2.45M shares), Farallon Capital Management LLC (2.33M shares), VANGUARD GROUP INC (2.29M shares), STATE STREET CORP (1.45M shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.36M shares).
This table shows the top 136 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.